子宫内膜癌治疗的研究进展(5)
[28] Vergote I，Powell M A，Teneriello M G，et al.Second-line lenvatinib in patients with recurrent endometrial cancer[J].Gynecol Oncol，2020，156(3)：575-582.
[29] Crusz S M，Miller R E.Targeted therapies in gynaecological cancers[J].Histopathology，2020，76(1)：157-170.
[30] Brooks R A，Fleming G F，Lastra R R，et al.Current recommendations and recent progress in endometrial cancer[J].CA Cancer J Clin，2019，69(4)：258-279.
[31] Ott P A，Bang Y J，Berton-Rigaud D，et al.Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer：Results From the KEYNOTE-028 Study[J].J Clin Oncol，2017，35(22)：2535-2541.
[32] Makker V，Rasco D，Vogelzang N J，et al.Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer：an interim analysis of a multicentre，open-label，single-arm，phase 2 trial[J].Lancet Oncol，2019，20(5)：711-718.
[33] Hao Z，Wang P.Lenvatinib in Management of Solid tumors[J].Oncologist，2020，25(2)：e302-e310.
(收稿日期：2020-03-20) (本文編辑：郎序莹), 百拇医药(佘远萍 黄玉梅)
[29] Crusz S M，Miller R E.Targeted therapies in gynaecological cancers[J].Histopathology，2020，76(1)：157-170.
[30] Brooks R A，Fleming G F，Lastra R R，et al.Current recommendations and recent progress in endometrial cancer[J].CA Cancer J Clin，2019，69(4)：258-279.
[31] Ott P A，Bang Y J，Berton-Rigaud D，et al.Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer：Results From the KEYNOTE-028 Study[J].J Clin Oncol，2017，35(22)：2535-2541.
[32] Makker V，Rasco D，Vogelzang N J，et al.Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer：an interim analysis of a multicentre，open-label，single-arm，phase 2 trial[J].Lancet Oncol，2019，20(5)：711-718.
[33] Hao Z，Wang P.Lenvatinib in Management of Solid tumors[J].Oncologist，2020，25(2)：e302-e310.
(收稿日期：2020-03-20) (本文編辑：郎序莹), 百拇医药(佘远萍 黄玉梅)